STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial

Definium Therapeutics said Wednesday that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of two large trials.

It’s the second major win for Definium in the past two months, following a Phase 3 success in major depression. 

In the Phase 3 anxiety study, 214 patients were randomly assigned to receive a single dose of DT120 — Definium “proprietary, pharmaceutically optimized” LSD pill — or a placebo. 

Continue to STAT+ to read the full story…